Skip to main content

Anti-Covid drug developed by DRDO

 

WHAT HAS HAPPENED?

The Drugs Controller General of India (DCG) has approved the emergency use of Drug 2-deoxy-D-glucose (2-DG) as an adjunet therapy in moderate to severe Covid-19 patients.

WHO DEVELOPED IT?

The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRD0), has developed the drug, In collaboration with Dr Reddy's Laboratories, Hyderabad.

WHEN & HOW IT WAS DEVELOPED?

In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and Found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Based on these results, Drugs Controller General of India's (DCG) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in COVID-19 patients in May 2020.

The DRDO, along with its industry partner DRL, Hyderabad, started the elinical trials to test the safety and efficacy of the drug in COVID-19 patients. In Phase-II trials conducted during May to October 2020, the drug was found to be safe in COVID-19 patients and showed significant
improvement in their recovery.
Phase Ila was conducted in six hospitals and Phase IIb clinical trial was conducted at 11 hospitals all over the country. Phase-II trial was conducted on 110 patients.

In efficacy trends,the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints. A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving  normalisation of specific vital signs parameters when compared to SOC.

PHASE 3

Based on successful results, DCGIl further permitted the Phase-1II clinical trials in November 2020. The Phase-IIl clinical trial was conducted on 220 patients between December 2020 to March 2021 at 27 COVID hospitals in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu. The detailed data of phase-IlI clinical trial was presented to DCGI.In 2-DG arm, significantly higher  proportion of patients improved symptomatically and became free from supplemental oxygen dependence(42% vs 31%) by Day-3, In comparison to SoC, indicating an early relief from Oxygen therapy/dependence.

PATIENTS ABOVE 65 YEARS

The similar trend was observed in patients aged more than 65 years.On May 01, 2021, DCGI granted permission for Emergency Use of this drug as adjunct therapy in moderate to severe COVID-19 patients.

2-DG, works by preventing the supply of glucose molecules to the cancerous cells, which need glucose for survival. With the drug stopping the glucose supply, the cells start dying.The drug is, however, not yet approved for cancer treatment.


HOW IT HELPS THE COVID PATIENT?

Being a generie molecule and analogue of glucose, it can be easily produced and made available in plenty in the country. The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique.



Comments

Post a Comment

Popular posts from this blog

MHA rolled out a "cyber volunteer" programme for "cyber hygiene promotion".एमएचए ने "साइबर स्वच्छता संवर्धन" के लिए "साइबर स्वयंसेवक" कार्यक्रम शुरू किया। .

The Ministry of Home Affairs (MHA) has rolled out a "cyber volunteer" programme for "cyber hygiene promotion".The volunteers will be utilised by the State police.The MHA informed the Lok Sabha, about the programme on 9th March 2021 . A group of "cyber crimé volunteers" will be raised through the cyber crime grievance portal. cybercrime.gov.in The volunteers will flag "unlawful content" on the Internet. The Cyber Crime Volunteer Framework has been rolled out as a part of cyber hygiene promotion. Aims to bring together citizens to contribute in the fight against cybercrime in the country and assist State/UT LEAs (law enforcement agencies) in their endeavor to curb cyber crimes. The State/UT Police Authorities will enroll the volunteers and assign them roles, as per their requirement. cyber Crime Volunteers Concept   Indian Cyber Crime Coordination Centre (14C) has been established under Ministry of Home affairs (MHA) to act as a nodal point at ...
Post a Comment
Read more

Mystery brain disease found in Canada

  WHAT HAS HAPPENED? An unknown brain disease has caused panic in the New Brunswick province of Canada after a string of cases were reported that involved memory loss, hallucinations and muscle atrophy. People living in the province became cognizant of the disease after a memo from the province's public health agency leaked last week, Which asked doctors to look for symptoms relate to Creutzfeldt-Jacob disease (CJD). CJD is a rare brain disease which is caused due to abnormally folded proteins called prions. Creutzfeldt-Jakob (KROITS-felt YAH-kobe) disease (CJD) is a degenerative brain disorder that leads to dementia and, ultimately, death. Creutzfeldt-Jakob disease symptoms can be similar to those of other dementia-like brain disorders, such as Alzheimer's disease. But Creutzfeldt-Jakob disease usually progresses much more rapidly. Transmitted by contact with infected tissue, such as during a transplant or from eating contaminated meat. CAUSES NOT KNOWN FOR CURRENT DISE...
Post a Comment
Read more

ANDHRA PRADESH STRAIN 15 TIMES MORE VIRULENT

  Experts are saying that a new Andhra Pradesh variant of the SARS-COV-2 virus is at least 15 times more virulent than the earlier ones. May be even stronger than the Indian variants of B. 1.617 and B. 1.618 . Speculation is still on regarding whether it is a new strain or the old N440K. The N440K variant was first discovered by Centre for Cellular and Molecular Biology (CCMB).However, data is still insufficient to confirm anythin. The impact of AP Strain Authorities say that the variant at present which is in circulation in Visakhapatnam is different from what we have seen during the first wave last year. Samples have been sent to CCMB for analysis, in order to find out which strain is in circulation right now.It has been observed that the new variant has shorter incubation period and the progress of the disease is much rapid. In the earlier cases, a patient infected with the virus would take at least a week to reach the hypoxia or dyspnea stage. But in the present context,...
Post a Comment
Read more